Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm
Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
- Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
- The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
- The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
- For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX